ERRATA

The April 1, 2007, article by Ruzzo et al, entitled “Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy” (J Clin Oncol 25:1247-1254, 2007), contained an error.

In the References section, reference 44 was given as: 44. Cunningham D, Norman AR, Chong G, et al: Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol 16:1305-1310, 2005.

Whereas it should have been: 44. Negri FV, Wotherspoon A, Cunningham D, et al: Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol 16:1305-1310, 2005.

DOI: 10.1200/JCO.2009.23.9228

The January 10, 2008, article by Kyriakou et al, entitled “High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome—Lymphoma Working Party of the European Group for Blood and Marrow Transplantation” (J Clin Oncol 26:218-224, 2008), contained an error in the online version. The DOI no. was given as 10.1200/JCO.2007.12.6219, and should have been 10.1200/JCO.2008.12.6219.

DOI: 10.1200/JCO.2009.23.6919

The March 10, 2009, article by Huo et al, entitled “Prediction of *BRCA* Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States” (J Clin Oncol 27:1184-1190, 2009), contained errors.

The following additional study support and disclaimers were inadvertently omitted:

Supported by National Cancer Institute, NIH, under RFA-CA-06-503, and through cooperative agreements with members of the Breast Cancer Family Registry, including Columbia University (U01 CA69398), Fox Chase Cancer Center (U01 CA69631), and Huntsman Cancer Institute (U01 CA69446). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the CFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the CFR.

DOI: 10.1200/JCO.2009.23.9244

The April 20, 2009, article by Galanis et al, entitled “Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study” (J Clin Oncol 27:2052-2058, 2009), contained errors.

In the Discussion section, the last sentences of the fourth and fifth paragraphs referred to the North American Brain Tumor Coalition, whereas it should have been the North American Brain Tumor Consortium.

The online version has been corrected in departure from the print.

DOI: 10.1200/JCO.2009.24.0408

The February 20, 2009, article by Thomas et al, entitled “Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma” (J Clin Oncol 27:843-850, 2009), contained an error in the spelling of E Lin. It was originally published as Elinor Lin, and should have been E Lin.

DOI: 10.1200/JCO.2009.24.3550

The May 1, 2009, article by Tandstad et al, entitled “Risk-Adapted Treatment in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: The SWENOTECA Management Program” (J Clin Oncol 27:2122-2128, 2009), contained errors.

In the Contributions section, Carl Langberg should have been acknowledged for collection and assembly of data.

The Acknowledgment was inadvertently omitted and should have been: “We thank all patients, investigators, and institutions involved in this study. We also thank Monika Andersson at the Tumörregisteret in Lund, Sweden, for collection of data and Ålesund Hospital for research funds.”

DOI: 10.1200/JCO.2009.24.3568

The May 1, 2009, article by Balsalobre et al, entitled “Autologous Stem-Cell Transplantation in Patients With HIV-Related Lymphoma” (J Clin Oncol 27:2192-2198, 2009), contained errors.

In the affiliations section, Hospital General Universitario Gregorio Marañón, Madrid, was incorrectly spelled as Hospital General Universidad Gregorio Marañón, Madrid. Also, Universidad de Cantabria, Santander, was incorrectly spelled as Universitario de Cantabria, Santander.

The online version has been corrected in departure from the print.

DOI: 10.1200/JCO.2009.24.0416

In the May 20, 2009, supplement, the abstract by Wood et al, entitled “Inhibition of ALK mutated neuroblastomas by the selective inhibitor PF-02341066” (J Clin Oncol 27:521s, 2009 [suppl; abstr 10008b]), contained an omission. It should have been noted that the authors reported no significant financial relationships to disclose.

The online version has been corrected in departure from the print.

DOI: 10.1200/JCO.2009.24.3576